REPL, BMGL, SPRC Lead Pre-Market Movers on May 29

Pre-market trading on May 29, 2026, saw sharp moves in Replimune Group (REPL), BMGL Inc. (BMGL), and SciSparc Ltd. (SPRC) following separate corporate developments. REPL shares surged 22% after the biotech reported positive interim data from its Phase 2 melanoma trial. The results, released ahead of the ASCO annual meeting, showed a 65% overall response rate in patients treated with its oncolytic immunotherapy. BMGL stock gained 18% after the company announced a strategic collaboration with a major pharmaceutical partner to develop its microbiome-based therapy, triggering a milestone payment of $50 million. Meanwhile, SPRC fell 11% after pricing a dilutive public offering of 3 million shares at $0.85 per share, below the previous close of $1.05.